|Title:||Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells|
|Authors :||Nallet, Sophie|
Hacker, David L.
Wurm, Florian M.
|Published in :||Vaccine|
|Publisher / Ed. Institution :||Elsevier|
|License (according to publishing contract) :||Licence according to publishing contract|
|Type of review:||Peer review (Publication)|
|Subjects :||Viral antibodies; Cell line; Inbred BALB C mice; Neutralization tests; Recombinant fusion proteins; Respiratory syncytial virus infections; Respiratory syncytial virus vaccines; Subunit vaccines; Viral fusion proteins; Virosomes; Transfection|
|Subject (DDC) :||615: Pharmacology and therapeutics|
|Abstract:||Although respiratory syncytial virus (RSV) causes severe lower respiratory tract infection in infants and adults at risk, no RSV vaccine is currently available. In this report, efforts toward the generation of an RSV subunit vaccine using recombinant RSV fusion protein (rRSV-F) are described. The recombinant protein was produced by transient gene expression (TGE) in suspension-adapted human embryonic kidney cells (HEK-293E) in 4 L orbitally shaken bioreactors. It was then purified and formulated in immunostimulating reconstituted influenza virosomes (IRIVs). The candidate vaccine induced anti-RSV-F neutralizing antibodies in mice, and challenge studies in cotton rats are ongoing. If successful in preclinical and clinical trials, this will be the first recombinant subunit vaccine produced by large-scale TGE in mammalian cells.|
|Departement:||Life Sciences and Facility Management|
|Organisational Unit:||Institute of Chemistry and Biotechnology (ICBT)|
|Publication type:||Article in scientific Journal|
|Appears in Collections:||Publikationen Life Sciences und Facility Management|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.